Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 1999

View Archived Issues

Deltagen and Pfizer establish target validation agreement

Abgenix: year-end 1998 highlights

Antex Biologics successfully completes phase I study of Helicobacter vaccine

Neotrofin shows positive results in phase II trial for Alzheimer's disease

Medtronic and Sofamor Danek finalize merger

Abgenix and Genentech form new antibody collaboration

Broad-spectrum antibacterial agents discovered at Daiichi

Nippon Soda discloses new series of inhibitors of cholesterol biosynthesis

New cardiac antiischemic agents developed by Lederle in Japan

Cytokine inhibitors from Merck presented in recent patent literature

Newly patented antiproliferative agents selectively inhibit protein farnesyltransferase

Medarex's first HuMAb-Mouse-derived antibody enters the clinic

U.K. launch announced for hemophilia B treatment

Japanese researchers describe amidine compounds for eating disorders

Agouron R&D products will round out Warner-Lambert's pipeline

Antipsychotic development candidate selected from carbazolone series by Spanish scientists

Proteasome inhibitors may have potential in refractory CLL

Temodal receives E.U. approval for recurrent gliobastoma multiforme

FDA advisory committee scheduled to discuss Relenza NDA

Medtronic and Arterial Vascular Engineering finalize merger

European Commission approves Betaseron for treatment of SPMS

InSite Vision licenses novel glaucoma treatment to Pharmacia & Upjohn

Canadian company formed to develop nucleic acid-based antiinfective drugs

Gliatech initiates ADCON-P pivotal clinical trial

Patent covering second-generation taxanes issues to Xechem

Abgenix initiates phase I trial with ABX-IL-8 in rheumatoid arthritis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...